Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 182   

Articles published

SNY 39.05 -0.77 (-1.93%)
price chart
Anticipated EPS Decrease for Sanofi SA (ADR) (SNY)
Wall Street await Sanofi SA (ADR) (NYSE:SNY) to release earnings on February, 9 before the open. Analysts forecast EPS of $0.69, down exactly $0.10 or 12.66% from 2014's $0.79 EPS.
Can Sanofi and Others Stop Zika?
Sanofi SA (ADR) (NYSE:SNY) has started a development program to contain the Zika virus. The virus was discovered in Africa in 1947.
Merck, Sanofi Exploring Potential End To Joint Venture In Europe  Benzinga
Sanofi Joins Race to Develop Zika Vaccine
Sanofi SA (ADR) (NYSE:SNY) has launched its vaccine development program for the rapidly spreading Zika virus. The virus was first detected in May 2015 in Brazil, and has since spread to almost 25 countries and territories in the Americas.
Sanofi SA (ADR) Scouts For New Cancer Treatments That Harness Immune Cells
Pharmaceutical giant Sanofi is partnering with two biotech companies -- Evotec AG in Hamburg, Germany, and Apeiron Biologics AG in Vienna, Austria - in its latest effort to develop a drug that harnesses the body's own immune system in the fight against ...
Sanofi Inks Deals, Diabetes and Immuno-Oncology in Focus
Google Inc, Sanofi SA (ADR) Partner Up For Diabetes Research
The Wall Street Journal has reported that Google Inc. (NASDAQ:GOOG) is going to partner up with European pharmaceutical giant Sanofi SA (NYSE:SNY) to research on monitoring and curing diabetes. While both the companies refused to disclose how ...
Google, Sanofi join forces on Diabetes monitoring and treatment  MarketWatch
Sanofi Teams Up with Google Life Sciences for Diabetes
Who will acquire Relypsa: Merck and Co or Sanofi SA?
Soon after, the Financial Times ran a slightly different story. Reporting from sources, it said Relypsa was itself preparing for a sale, and drug-makers like GlaxoSmithKline plc (ADR) (NYSE:GSK), Sanofi SA and Switzerland's Galenica might be possible ...
EXCLUSIVE: Relypsa Being Evaluated By 3-4 Potential Acquirers; Sanofi Seen ...  Benzinga
Regeneron Pharmaceuticals Inc And Sanofi SA (ADR) Win EU Nod For Cholesterol ...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), a leader in the biotech sector, and Sanofi SA (ADR) (NYSE:SNY), the French pharmaceutical giant, have fetched a victory adding to their success in the pharmaceutical sector.
Company Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi SA ...  Smarter Analyst
Sanofi: Sanofi Pasteur to Fund Human Vaccines Project
Sanofi SA (ADR) (NSYE:SNY) vaccine division, Sanofi Pasteur, has finalized a deal with the Human Vaccines Project Inc. to partially provide funds for research.
Sanofi: Will Collaborations Help It Excel In Oncology And Gram-Negative Infections
Sanofi SA (ADR) (NYSE:SNY) and Innate Pharma (OTCMKTS:IPHYF) have announced a finalized research deal, as well as a licensing agreement for the acquisition of Innate Pharma's new proprietary technology.
Buzz Stocks: MGM Resorts International, Allergan PLC, and Sanofi SA (ADR)
Sanofi SA believes that its sales of Lantus insulin will fall between 4% and 8% through 2018. Technically, the stock has fallen 11.7% since mid-August's high of $54.98, and is now set to end beneath its 10-day and 20-day moving averages for the first ...